Introduction
============

Nasopharyngeal carcinoma (NPC) is a squamous epithelial malignant tumor arising from the lateral wall surface of nasopharynx with a high incidence in southern China, Japan and Southeast Asia [@B1]. Prevalence survey shows that the southern Chinese have the highest incidences of NPC in the world [@B2]. Genetic, environmental and microbial factors are thought to be involved in the carcinogenesis of NPC [@B3]. Due to the high sensitivity of NPC cells to ionizing radiation, radiotherapy is the main modality for treatment of NPC. However, some NPC patients have a poor prognosis because of no suitable biomarker for early detection and poor understanding of the molecular mechanisms [@B4]-[@B6]. Thus, the further understanding of the underlying mechanisms of NPC tumorigenesis will contribute to develop novel options for the diagnosis and therapy of NPC.

Calmodulin (CaM) kinases are a group of serine/threonine kinases that catalyze various biological processes, such as neurotransmitter release, muscle contraction, proliferation, differentiation, and apoptosis [@B7]-[@B9]. Pregnancy-upregulated nonubiquitous calmodulin kinase (PNCK) is a novel member of the CaM kinase family, which shares 45-70% sequence similarity with the kinase domain of the CaM kinase family. PNCK is widely expressed in the central nervous system and in a variety of tissues including heart, breast, brain, uterus, and stomach [@B10]. Recent studies have found that PNCK play critical roles in cytoplasmic and nuclear signal transduction, thereby regulating various biological processes [@B11],[@B12]. However, the molecular mechanism by which PNCK contributes to the malignant NPC remains largely unknown.

Therefore, it is critical to elucidate the mechanism by which PNCK exerts its functional role in the progression of NPC. In the present study, for the first time, we explored the functional relevance of PNCK using NPC tissue samples, cell lines and animal models. For mechanical investigation, transcriptome analysis was performed and many signaling pathways were found to be altered. Analysis of clinical samples revealed a significant elevation of PNCK in NPC. Moreover, *in vitro* and *in vivo* studies showed that knockdown of PNCK substantially inhibited growth and induced apoptosis in human NPC cells. In addition, transcriptomic analysis revealed that PI3K/AKT/mTOR pathway was remarkably changed, which may be responsible for PNCK-mediated cellular behaviors. Taken together, our study indicates that the PNCK could be a target for treatment of NPC.

Materials and methods
=====================

Patients and tissue specimens
-----------------------------

In this study, 8 freshly frozen NPC and 10 normal nasopharyngeal tissue were collected in Fujian Cancer Hospital between January 2017 and March 2017. Then, paraffin-embedded specimens of NPC (n=10) and normal tissues (n=10) were used for gene expression analysis. These patients had no radiotherapy or chemotherapy history before biopsy. NPC was pathologically confirmed by two senior pathologists who were blinded to the clinical information of patients. This study was approved by the Institute Research Medical Ethics Committee of Fujian Cancer Hospital, Fujian Medical University Cancer Hospital (\#2017-051-01), with a written consent form signed by patients.

Cell culture
------------

The human NPC cell lines (CNE-2, CNE-1 and 5-8F) were purchased from the Cell Resource Center (Shanghai Institutes for Biological Sciences, China Academy of Sciences). NPC C666-1 cell line was a gift form Prof. Geoge S.W. Tsao of the University of Hong Kong. Cells were cultured in Dulbecco\'s Modified Eagle Medium supplemented with 10% FBS, 100 U/mL penicillin, and 100 U/mL streptomycin, and were maintained at 37°C in 5% CO~2~ incubator.

Transcriptome analysis
----------------------

Total RNAs were extracted using TRIZOL Reagent (Life technologies, Carlsbad, CA, USA) following the manufacturer\'s instructions and checked for RNA integrity by an Agilent Bioanalyzer 2100 (Agilent technology, Santa Clara, CA, USA). Qualified total RNA was further purified by RNeasy microkit (QIAGEN, GmBH, Germany) and RNase Free DNase Set (QIAGEN, GmBH, Germany). Total RNAs were amplified, labeled and purified by using GeneChip 3\'IVT Express Kit (Affymetrix, Santa Clara, CA, USA) followed the manufacturer\'s instructions to obtain biotin labeled RNA. Array hybridization and wash was performed using GeneChip® Hybridization, wash and stain Kit (Affymetrix, Santa Clara, CA) in Hybridization Oven 645 (Affymetrix, Santa Clara, CA) and Fluidics Station 450 (Affymetrix, Santa Clara, CA) followed the manufacturer\'s instructions. Slides were scanned by GeneChip® Scanner 3000 (Affymetrix, Santa Clara, CA, US) and Command Console Software 3.1 (Affymetrix, Santa Clara, CA, US) with default settings. Differentially expressed genes with statistical significance, a fold change filtering between two samples was performed and the default threshold was ≥1.5 fold-change. The biological processes were identified using Ingenuity Pathway Analysis (<http://www.ingenuity.com/products/ipa>).

Cell proliferation assay
------------------------

Cell proliferation was determined using MTT \[3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide\] assay (Roche Diagnosis). Briefly, cells were plated into 96-well plates at the density of 2,000 cells/well in triplicates and cultured in DMEM supplemented with 10% FBS. After 24 h incubation at 37˚C, 20 μl of 5mg/ml MTT was added and further cultured for 4 hours. After discard of culture media, 100 μl/well of dimethyl sulfoxide was added to well and the optical density was measured at 490 nm using a Microplate Reader (Bio-Rad, Hercules, CA, USA). All experiments were performed at least three times.

Apoptosis assay
---------------

Cells were collected by trypsinization, washed twice with PBS and fixed in 80% ice-cold ethanol in PBS. Then, cells (≥5×10^5^) were re-suspended in 200 μl binding buffer and incubated with 10 μl staining solution containing FITC-conjugated annexin V antibody (cat: 88-8007, eBioscience, CA, USA). After incubation for 15 min at room temperature in the dark the apoptotic cells were detected by flow cytometer following the manufacturer\'s instruction.

Caspase 3/7 activity assay
--------------------------

The Caspase 3/7 activity was determined in each group using a commercial kit (Caspase-Glo® 3/7 Assay, Promega, Shanghai) according to the manufacturer\'s instruction. In brief, 100μl Caspase3/7 reagent was added to each well of the plates and incubated at room temperature for 2h. Absorbance values were detected using a microplate reader at A405nm (Tecan infinite, Mannedorf, Switzerland).

Immunohistochemical staining
----------------------------

The paraffin-embedded blocks were cut into 3-μm thickness sections and mounted on glass slides coated with poly-L-lysine, deparaffinized with xylene and rehydrated with gradient ethanol. The slides were heated and incubated in a 10 mM citrate buffer. After inactivating endogenous peroxidase by H~2~O~2~, the slides were incubated with primary antibody targeting PNCK (1:20, HPA007458, Sigma, USA) for 1 h followed by incubation with biotinylated secondary antibody. The staining intensity was considered as negative (0), weak (1), moderate (2), or strong (3). The percentage of positive staining was scored as 0% (0), \<25% (1), 25-50% (2), 50-75% (3), or \>75% (4). The immunostainings of PNCK was evaluated by two pathologists without knowledge of patient characteristics and a consensus was provided on staining patterns.

Real time PCR
-------------

Total RNA from cells or tissues was extracted using Trizol reagent (Life Technologies), and reversely transcribed into cDNA. The expression levels of indicated genes were measured by real time PCR on ABI 7700 system using the following primers: forward PNCK-F: 5\'-TGACATCTCAGAATCAGCCAAAG-3\', reverse PNCK-R 5\'-GTGTCCGAGCAAAGTTCTTCC-3\'; GAPDH-F: 5\'- TGACTTCAACAGCGACACCCA-3\', reverse GAPDH-R 5\'- CACCCTGTTGCTGTAGCCAAA-3\'. PCR was conducted with the following parameters: an initial denaturation step of 30 seconds at 95°C; and 94°C (30 seconds), 58°C (30 seconds), 72°C (50 seconds) in a total 35 cycles with a final extension step at 72°C for 5 min. All samples were normalized to GAPDH and expression fold changes were calculated using 2-ΔΔCt methods.

Western blotting
----------------

Cells were collected, lysed in RIRA lysis buffer, and subject to centrifugation at 12,000 rpm for 10min. The protein concentration was determined using a BCA protein assay kit (Beyotime, Haimen, China). Equal amounts of protein lysates were separated by denaturing sodium dodecyl sulfate-polyacrylamide gels and transferred to nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA). After blocking in 5% nonfat dry milk, the membranes were incubated with primary antibodies targeting PNCK (1:500, Sigma, USA), PI3K (1:1000, Cell Signaling Technology, USA), AKT (1:1000, Cell Signaling Technology, USA), mTOR (1:1000, Cell Signaling Technology, USA), p-PI3K (1:1000, Abcam, USA), p-AKT (1:2000, Cell Signaling Technology, USA), p-mTOR (1:5000, Cell Signaling Technology, USA) and GAPDH (1:1000, Santa Cruz, USA) at 4℃ overnight. The membranes were rinsed with PBST (PBS with 0.1% Tween-20) three times and incubated with the appropriate secondary antibodies for 1h at room temperature. The protein bands were detected using an enhanced chemiluminescence kit (GE Healthcare, Piscataway, NJ).

Xenograft model
---------------

Female athymic BALB/c mice (4-6 weeks old) were purchased from Shanghai Slac Laboratory Animal Co. Ltd. (Shanghai, China). All procedures for animal studies were approved by Animal Care and Use Committee of Fujian Cancer Hospital. Wild-type or PNCK-knockdown CNE-2 cells were injected subcutaneously into nude mice (n = 10 per group). After 10 days, tumors were measured with calipers once a week for five weeks. Tumor volume was calculated according to the following formula: V = π/6 × L × W^2^ where V= volume (mm^3^), L = length (mm), and W = width (mm) [@B13]. At the end of experiments, mice were euthanized and tumors were excised and weighed. For measurement of bioluminescence imaging density, mice were anesthetized with isoflurane gas and injected intraperitoneally with 150 mg/kg D-luciferin aqueous solution. The images were captured 10 min following injection using an IVIS 50 Imaging system (Caliper Life Sciences, Alameda, CA, USA). Signal intensity was quantified within a region of interest.

Statistical analysis
--------------------

All statistical analyses were performed with SPSS 17.0. The data were presented as the mean ± standard deviation (S.D.) of at least three independent experiments. Differences between groups were compared using Student\'s*t* test or ANOVA. All data were considered significant difference if P values were \< 0.05.

Results
=======

Up-regulation of PNCK in human NPC
----------------------------------

Firstly, mRNA and protein levels of PNCK in NPC cancerous and normal tissues were determined by real-time PCR and immunohistochemical staining. The results (Fig [1](#F1){ref-type="fig"}A and B) showed that the mRNA and protein levels of PNCK were higher in the NPC tissues compared to the normal tissues. Furthermore, Figure [1](#F1){ref-type="fig"}C showed that PNCK in four NPC cell lines (CNE-2, C666-1, CNE-1 and 5-8F) was detectable, indicating that PNCK is commonly possessed by NPC cells.

ShRNA-mediated PNCK knockdown inhibited growth and induced apoptosis in NPC cells
---------------------------------------------------------------------------------

To investigate the role of PNCK in the growth of NPC cells, we knocked-down the expression of PNCK by shRNA in CNE-2 cells (Figure [2](#F2){ref-type="fig"}A) at the mRNA and protein levels as confirmed by real-time PCR and western blot analysis (Figure [2](#F2){ref-type="fig"}B). The growth and proliferation of PNCK knocked-down cells was inhibited compared to control cells demonstrated by Celigo Cell Counting (Figure [2](#F2){ref-type="fig"}C) and MTT assays (Figure [2](#F2){ref-type="fig"}D). Furthermore, the PNCK knockdown could enhance the programmed cell death (apoptosis), as showed in Annexin V-FCM assay (Figure [2](#F2){ref-type="fig"}E). Moreover, the caspase 3/7 activity in PNCK knockdown tumor cells was elevated in ELISA assay (Figure [2](#F2){ref-type="fig"}F).

CRISPR-Cas9-mediated PNCK knockout induced apoptosis in NPC cells
-----------------------------------------------------------------

To completely deplete PNCK, CNE-2 cells were co-transfected with CRISPR-Cas9 and sgRNA against the PNCK (Figure [3](#F3){ref-type="fig"}A). Western blot analysis showed that PNCK was completely silenced by CRISPR/Cas9-mediated gene knockout (Figure [3](#F3){ref-type="fig"}B). In addition, ELISA assay showed that PNCK knockout significantly increased the caspase 3/7 activity in CNE-2 cells (Figure [3](#F3){ref-type="fig"}C). Consistently, flow cytometric analysis revealed an elevated apoptosis in PNCK knockout CNE-2 cells (Figure [3](#F3){ref-type="fig"}D). Collectively, these data indicated that knockout of PNCK induced apoptosis in NPC cells.

*In vivo* effect of PNCK knockdown on NPC cell growth
-----------------------------------------------------

To explore if the *in vitro* effect of PNCK-knockdown can be translated *in vivo*, the PNCK knockdown CNE-2 cells were injected subcutaneously into the flank of BABL/c nude mice. After 2 weeks later, the tumor volume in each mouse was measured once a week for consecutive 5 weeks. There was a significant reduction of tumor volume and bioluminescence imaging (BLI) signals in tumors formed by PNCK-knockdown CNE-2 cells compared to those formed by control cells (Figure [4](#F4){ref-type="fig"}A and B). Similarly, the lack of PNCK significantly inhibited the tumor weight tumors at the end of this study as compared with the tumors formed by wild-type NPC cells (Figure [4](#F4){ref-type="fig"}C). Collectively, these data indicate that inhibition of PNCK exhibits anti-proliferative effect in *in vivo* model of xenograft nude mice.

Effects of PNCK depletion on PI3K/AKT/mTOR signaling pathway
------------------------------------------------------------

Subsequently, genome-wide expression profiling was conducted to determine the differentially expressed genes in the CNE-2 cell line upon PNCK knockdown. Total RNAs were extracted from the wild type or PNCK-knockdown CNE-2 cells and subjected to microarray analysis using Affymetrix GeneChip PrimeView Human Gene Expression Arrays. The purity (A260/280 value) of all RNA samples prepared was \>1.95 (Table [1](#T1){ref-type="table"}).

Transcriptomic analysis revealed 589 genes were up-regulated and 589 genes were down-regulated (fold change \>=1.5, P-value\<0.05). Volcano plots and heat maps of these differentially expressed genes visualized a clear distinction between wild type and PNCK knockdown CNE-2 cells (Figure [5](#F5){ref-type="fig"}A and B). Moreover, pathway analysis using Ingenuity Pathway Analysis (IPA) revealed significant changes of PI3K/AKT/mTOR signaling pathway. Furthermore, western blot analysis showed that interference with PNCK expression reduced the phosphorylation levels of PI3K, AKT and mTOR in CNE-2 cells (Figure [5](#F5){ref-type="fig"}C). There were no significant changes of total PI3K, AKT and mTOR between control and shPNCK groups. Collectively, these findings reveal that depletion of PNCK inhibits PI3K/AKT/mTOR signaling pathway in NPC cells.

Discussion
==========

In this study, the high expression of PNCK was detected in NPC tumor tissues and NPC cell lines. Silencing of PNCK inhibited cell proliferation and induced apoptosis *in vitro*. Moreover, animal experiments revealed that PNCK knockdown suppressed tumor growth. In addition, transcriptomic analysis indicated substantial changes in the gene expression and various signaling pathways involved in tumor growth and development. We conclude that PNCK plays a potential oncogenic role in NPCs by promoting NPC cell proliferation and tumor growth, a new insight into understanding the mechanisms of NPC tumorigenesis and exploring the potential therapeutic targets for NPCs.

PNCK, a newly discovered CaM kinase, is elevated in the mouse mammary gland during pregnancy in a subset of epithelial cells [@B10]. Similarly, PNCK is up-regulated in the transformation of human breast cancer, suggesting that PNCK may be involved in mammary development and carcinogenesis [@B11]. In addition, high expression of PNCK is reported in clear cell renal cell carcinoma (ccRCC), which is correlated with shorter overall survival, an independent prognostic factor for survival in ccRCC [@B14]. Recently, studies have revealed that PNCK induces ligand-independent EGFR degradation by probable perturbation of the Hsp90 chaperone complex, representing an attractive target in EGFR-regulated oncogenesis [@B15]-[@B17]. Additionally, ectopic expression of PNCK causes trastuzumab resistance in HER-2 amplified breast cancer via PTEN-mediated process, suggesting that inhibition of PNCK may be a novel strategy to overcome drug resistance [@B18].

Gene expression profiling, pathway analysis and IPA analysis by comparison of with PNCK-depleted NPC cells with its wild-type cells revealed that hundreds of genes were significantly altered after PNCK knockdown, especially the signaling pathways (i.e., PI3K/AKT/mTOR, IL-1 and integrin signaling) and biological events (i.e., cell deaths and survival, apoptosis, cancer pathogenesis, cellular development). The PI3K/AKT/mTOR pathway is a survival pathway constitutively activated in many types of cancer. This pathway is considered as an attractive therapeutic target for cancer treatment because it serves as a convergence point, controlling the multiple biological processes that contribute to the initiation and progression of cancer [@B22],[@B23]. It has been reported that blocking PI3K/AKT signaling attenuates metastasis of NPC cells by inducing mesenchymal-epithelial reverting transition [@B24]. Moreover, genetic variations in the PI3K/AKT/mTOR pathway are suggested to be involved in the distant metastasis in NPC patients [@B25]. Accordingly, many studies have performed the preclinical evaluation of small-molecule inhibitors that target PI3K-mTOR as a novel therapeutic drug in NPC [@B26]-[@B28]. Consistently, our study validated that interference with PNCK expression reduced the phosphorylation levels of PI3K, AKT and mTOR, which contributed to the inhibition of PI3K/AKT/mTOR signaling pathway in NPC cells.

However, there are several limitations of this study, such as small sample size and lack of follow-up data that could have provided possible association between PNCK expression and clinicopathologic characteristics such as TNM stage, age, gender and survival. Although we found that PI3K/AKT/mTOR pathway is regulated by PNCK, the detailed regulation mechanisms are not understood. Therefore, a further investigation into the underlying molecular interaction between PNCK and PI3K/AKT/mTOR in NPC is needed.

In conclusion, the present study, for the first time, demonstrated the up-regulation of PNCK in NPC. Interference with PNCK expression exhibited an anti-oncogenic role in NPC cells both*in vitro* and *in vivo*. Moreover, transcriptomic analysis revealed that PNCK depletion induced substantial changes of gene expression and transduction signals. These findings indicate that PNCK might be a potential therapeutic target of NPC.
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![**Up-regulation of PNCK in human NPC.** The expression of PNCK in NPC tumor tissues and the matched adjacent nasopharyngeal tissues was detected by real time PCR (A) and immunohistochemical staining (B). (C) Western blot was performed to detect the expression of PNCK in four NPC cell lines including CNE-2, C666-1, CNE-1 and 5-8F.](jcav10p6925g001){#F1}

![**ShRNA-mediated PNCK knockdown inhibited growth and induced apoptosis in NPC cells.** Human NPC CNE-2 cells were infected with PNCK shRNA using a lentivirus-GFP system (A). After 72 h, silencing of PNCK expression was validated by using real time PCR (B) and western blot analysis (C). Celigo Cell Counting (C) and MTT assays (D) were conducted to measure the effect of PNCK knockdown on cell viability. The effect of PNCK knockdown on cell apoptosis was assessed by determining the apoptotic cell death (E) and caspase 3/7 activity (F). \*\* P\<0.01, \*\*\* P\<0.001.](jcav10p6925g002){#F2}

![**CRISPR-Cas9-mediated PNCK knockout induced apoptosis in NPC cells.** Human NPC CNE-2 cells were co-transfected with CRISPR-Cas9 and sgRNA against the PNCK (A). After 72 h, silencing of PNCK expression was validated by using western blot analysis (B). The effect of depletion of PNCK on cell apoptosis was assessed by determining the caspase 3/7 activity (C) and apoptotic cell death (D). \*\* P\<0.01.](jcav10p6925g003){#F3}

![**Depletion of PNCK inhibited tumor growth*in vivo*.** The wild-type or PNCK-knockdown CNE-2 cells were injected subcutaneously into the flank of nude mice. Tumor diameters were measured at a regular interval of one week for up to five weeks, and the tumor volume was calculated (A). (B)*In vivo* bioluminescence imaging of tumors in wild-type or PNCK-knockdown CNE-2 tumor bearing mice. The xenografts were harvested after five weeks. The pictures of the tumors were taken, and the weights of the tumors were analyzed (C). \*\* P\<0.01, \*\*\* P\<0.001.](jcav10p6925g004){#F4}

![**Effects of PNCK depletion on PI3K/AKT/mTOR signaling pathway.** Volcano plots (A) and cluster analysis (B) in NPC cells after depletion of PNCK. (C) The expression of PI3K, AKT and mTOR and their phosphorylation levels in NPC cells were evaluated by western blot.](jcav10p6925g005){#F5}

###### 

Preparation of RNAs for microarray analysis\*.

  Sample number   Name   Thermo NanoDrop 2000   
  --------------- ------ ---------------------- ------
  G3088-1         NC     491.8                  1.96
  G3088-2         NC     505.6                  1.97
  G3088-3         NC     522.8                  2.02
  G3089-1         KD     491.1                  1.97
  G3089-2         KD     485.5                  1.97
  G3089-3         KD     500.1                  1.97

\*NC: control wild-type CNE-2 cells; KD: PNCK knockdown CNE-2 cells. A total of six samples were subjected to microarray analysis with three samples in each group.
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